Hiroyuki Moriuchi

Prof. Hiroyuki Moriuchi

Graduate School of Biomedical Sciences, Nagasaki, Japan
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Brain and Development
Verified
Journal Article
Closed access
ASAyako Sakamoto
Ayako Sakamoto
HMHiroyuki Moriuchi
Hiroyuki Moriuchi
JMJunko Matsuzaki
Junko Matsuzaki
KMKazunori Motoyama
Kazunori Motoyama
MMMasako Moriuchi
Masako Moriuchi

1 February 2013 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
HMHiroyuki Moriuchi
Hiroyuki Moriuchi
HMHideaki Masuzaki
Hideaki Masuzaki
HDHiroshi Doi
Hiroshi Doi
SKShigeru Katamine
Shigeru Katamine

1 February 2014 in Vaccine
Verified
Journal Article
Closed access
MMMasami Miyakawa
Masami Miyakawa
HYHiroshi Yoshino
Hiroshi Yoshino
LYLay Myint Yoshida
Lay Myint Yoshida
EVEmilia Vynnycky
Emilia Vynnycky
HMHideki Motomura
Hideki Motomura
HMHiroyuki Moriuchi
Hiroyuki Moriuchi

Verified
Journal Article
Open access
PDF file
IMIchiro Morioka
Ichiro Morioka
YKYasumasa Kakei
Yasumasa Kakei
TOTakashi Omori
Takashi Omori
KNKandai Nozu
Kandai Nozu
Kazumichi FujiokaKazumichi Fujioka
Kazumichi Fujioka
AOAkira Oka
Akira Oka
Our aims were to determine the clinical impact of oral valganciclovir (VGCV) in infants aged ≤2 months with congenital cytomegalovirus (CMV) disease and evaluate the efficacy of VGCV when initiated beyond the neonatal period. The multicenter, single-arm, open-label clinical trial was conducted in Japan. Twenty-five infants aged ≤2 months with congenital CMV disease involving the central nervous system were enrolled and treated with VGCV for 6 months. The primary endpoint was the change in the whole blood CMV load before and after treatment. The secondary endpoint was the change in the auditory brainstem response (ABR) before and after treatment. Changes in ABR were assessed between the younger and older age groups (≤ and >30 days at treatment initiation). Of the 25 patients, one was excluded owing to epilepsy before VGCV administration. The median change in the CMV DNA level in whole blood was −246.0 IU/mL. The best ear and total ear assessments based on ABR were categorized as (improved + unchanged) after treatment for 100% and 93.8%, respectively. No differences in hearing efficacy were observed between the younger and older age groups. Oral VGCV is a potential therapeutic option for treating infants aged ≤2 months with congenital CMV disease.

15 October 2014 in Pediatrics International
Verified
Journal Article
Open access
PDF file
AKAtsuko Kitamura
Atsuko Kitamura
TKTatsuro Kondoh
Tatsuro Kondoh
MNMitsuru Noguchi
Mitsuru Noguchi
THTeppei Hatada
Teppei Hatada
STShohei Tohbu
Shohei Tohbu
HMHiroyuki Moriuchi
Hiroyuki Moriuchi
Background: Despite the fact that functional lower urinary tract symptoms are common among people with Down syndrome (DS), their voiding function has not been studied precisely. Our goal was to assess the lower urinary tract functions in DS.Methods: Fifty‐five DS children aged 5–15 years old and 35 age‐matched control children were evaluated by ultrasonography and uroflowmetry.Results: Eleven (20%) DS children had no uresiesthesia, 21 (38%) were urinated under guidance, nine (16%) urinated fewer than three times a day, two (4%) urinated more than 10 times a day, three (5%) used diapers, and 26 (47%) had urinary incontinence. Seven (13%), 15 (27%), and 10 (18%) DS children had weak, prolonged and intermittent urination, respectively, and seven (13%) had urination with straining. In contrast, none of the control subjects had urinary problems. In the uroflowmetrical analysis, 10 (18%), 20 (37%), 11 (20%) and five (9%) DS children showed “bell‐shaped,” “plateau,” “staccato” and “interrupted” patterns, respectively; the remaining nine (16%) could not be analyzed. In contrast, 21 (60%), one (3%), four (11%), three (9%) and two (6%) control subjects showed bell‐shaped, tower‐shaped, plateau, staccato and interrupted patterns, respectively; the remaining four (11%) could not be analyzed. Residual urine was demonstrated in four (7%) DS children and one (3%) control child.Conclusions: Lower urinary tract symptoms and abnormal uroflowmetry findings, which can lead to further progressive renal and urinary disorders, are common in DS children. Therefore, lower urinary tract functions should be assessed at the life‐long regular medical check‐ups for subjects with DS.

1 April 2012 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
KMKiyoshi Migita
Kiyoshi Migita
HIHiroaki Ida
Hiroaki Ida
HMHiroyuki Moriuchi
Hiroyuki Moriuchi
KAKazunaga Agematsu
Kazunaga Agematsu